Most write-ups of BPC-157 open with the same line: "no human trials." That isn't quite true, and the real story is more interesting. BPC-157 research did reach human beings — twice, in a formal drug-development programme run by a Croatian pharmaceutical company more than two decades ago. The trials happened. The results, as far as the public record goes, never made it into a peer-reviewed journal. This post looks at what those studies were, why the gap matters more than the conspiracy theories around it, and where that leaves the question of whether BPC-157 is legal in Australia.

If you want the background first, our BPC-157 profile covers the basics, and the wider peptides index has the rest of the compounds we track.

What is BPC-157, and why does the human evidence question keep coming up?

BPC-157 is a synthetic 15-amino-acid sequence derived from a protein found in human gastric juice — hence "body protection compound." It is not approved as a medicine anywhere in the world. The reason the evidence question never goes away is that the marketing claims (tendons, ligaments, gut lining, muscle tears) sit almost entirely on rodent data, while the compound is sold and injected as though it had a clinical file behind it.

The clearest recent accounting came from a 2025 systematic review in HSS Journal, the musculoskeletal journal of the Hospital for Special Surgery. The authors screened 544 articles published between 1993 and 2024 and included 36. Of those, 35 were preclinical and one was clinical — a small retrospective series in which 7 of 12 patients reported relief lasting more than six months after intra-articular BPC-157 for chronic knee pain. That is a chart review, not a controlled trial. No completed, controlled human efficacy trial of BPC-157 has been published.

The trials that did happen: Pliva, PL 14736 and the gut

Long before the peptide became a gym-forum staple, the Croatian pharmaceutical company Pliva was developing it as a drug candidate under a series of code names — PL-10, PLD-116, and finally PL 14736. The target indication was not tendon repair. It was inflammatory bowel disease, specifically ulcerative colitis.

Phase 1: rectal dosing in healthy volunteers

A Phase 1 study by Veljača and colleagues assessed the safety, tolerability and pharmacokinetics of PL 14736 given rectally to healthy male volunteers. The reported conclusion was that it was safe and well tolerated, and that the data supported moving to a controlled efficacy study. This work appears in the literature as a conference abstract (Gut, 2003) rather than a full paper — which limits how much detail anyone can scrutinise.

Phase 2: an enema trial that never reached a journal

On the strength of that, a multicentre, randomised, double-blind, placebo-controlled Phase 2 study of PL 14736 enema in mild-to-moderate ulcerative colitis was run and presented in abstract form (Gastroenterology, 2005). That is a properly designed trial by any standard — randomised, blinded, placebo-controlled, multicentre.

And then nothing. We could not locate a full peer-reviewed publication of its results in any gastroenterology journal. Pliva was acquired by Barr Pharmaceuticals in 2006 and Barr by Teva in 2008, and the programme does not appear to have continued publicly under any owner.

Why "unpublished" isn't the same as "suppressed"

This gap gets used in two opposite directions online, and both are overreaches.

One camp treats the missing publication as proof of a cover-up: a cheap, unpatentable peptide that worked too well. The other treats the mere existence of a Phase 2 trial as evidence the compound is clinically validated. Neither holds.

What is defensible is the boring middle. Trials go unpublished for several reasons, and the single most common one across medicine is that the result was null or unimpressive. Corporate restructuring during two acquisitions is a plausible contributor, as is a commercial decision unrelated to efficacy. Without the data, all of these remain hypotheses. The honest reading is that an unpublished trial contributes essentially nothing to the evidence base in either direction — you cannot bank a result you have never seen.

The route mismatch nobody mentions

Here is the detail that gets lost when the Pliva programme is cited as "BPC-157 has human safety data."

Both human studies delivered the peptide into the lower bowel — rectally in Phase 1, as an enema in Phase 2 — to act locally on inflamed colonic tissue. That is a fundamentally different exposure profile from a subcutaneous injection intended to reach a tendon, or a capsule swallowed for systemic effect. Local mucosal tolerability in healthy men tells you very little about the safety of repeated systemic dosing over weeks or months, which is how the compound is actually used today.

So the one place BPC-157 was formally tested in humans is the one indication almost nobody buys it for. The 2025 narrative review in Current Reviews in Musculoskeletal Medicine reached a similar bottom line from the orthopaedic side: mechanistically interesting, biologically plausible, minimal human data, and it should be treated as investigational.

Is BPC-157 legal in Australia?

No — not without authority. This is the part Australian readers need to be precise about.

  • Schedule 4 + Appendix D since 1 June 2024. The TGA added BPC-157 to Schedule 4 (prescription only) of the Poisons Standard and listed it in Appendix D, clause 5. Appendix D is the restriction that makes possession without authority illegal, not merely supply. Australia was the first country to schedule BPC-157 by name.
  • The trigger was importation. The TGA's decision followed dozens of referrals for personal importation of BPC-157 received from mid-2022 onwards.
  • Not approved anywhere. There is no TGA registration, no FDA approval, no EMA approval.
  • Banned in sport. WADA has prohibited BPC-157 since 2022, and Sport Integrity Australia maintains a dedicated advisory page for athletes.
  • Overseas status hasn't rescued it either. In the United States, BPC-157's compounding position shifted through 2026 — it left the FDA's Category 2 list in April after the underlying nomination was withdrawn, and a July advisory committee vote was exactly that: advisory. It is still not lawfully compoundable.

The practical upshot for an Australian reader: this is a prescription-only, possession-restricted substance with no approved indication, and no published controlled human efficacy trial anywhere in the world.

What would actually change the picture

One well-run, published randomised controlled trial in a defined injury — with a registered protocol, a named institution and results in a journal. Nothing less.

A caution worth stating plainly here: registry listings circulating in 2026 as "the first human BPC-157 trial" should be checked before they are believed. ClinicalTrials.gov entries are self-submitted and are not peer reviewed or vetted for scientific merit, and the registry has carried demonstration and placeholder records for peptide compounds. Before treating any listing as real, look for a sponsor that is a verifiable organisation, a named principal investigator, a real institution, and ideally a published protocol. A recruiting status alone means very little.

Want the next credible development on this compound in your inbox rather than your feed? Join the free updates list.

FAQ

Are there any human trials of BPC-157?

Yes, historically — a Phase 1 rectal safety study and a randomised, placebo-controlled Phase 2 enema trial in ulcerative colitis, both run by Pliva under the code PL 14736 and both reported only as conference abstracts. No full results were published in a peer-reviewed journal, and no controlled human efficacy trial of BPC-157 has been published to date.

Is BPC-157 legal in Australia?

No. Since 1 June 2024 BPC-157 has been Schedule 4 (prescription only) with an Appendix D, clause 5 listing, which makes possession without authority illegal. It is not approved by the TGA or any other regulator.

Why was the BPC-157 ulcerative colitis trial never published?

Nobody outside the companies involved knows. Plausible explanations range from a null or unimpressive result — the most common reason trials go unpublished across medicine — to disruption from Pliva's acquisition by Barr and then Teva. Absence of publication is not evidence that the drug worked.

What does BPC-157 research actually show?

Consistent, repeated benefit in rodent models of tendon, muscle, ligament and gut injury, with plausible mechanisms involving angiogenesis and growth factor signalling. A 2025 HSS Journal systematic review found 35 of 36 included studies were preclinical, with the single clinical entry being a 12-patient retrospective chart review.

Sources

This article is general information, not medical advice. BPC-157 is an investigational compound that is not approved as a medicine in any country and is a Schedule 4 + Appendix D substance in Australia. retatrutide.net.au is independent, sells nothing, and does not direct readers to suppliers.